Amarantus Appoints Robert Farrell, J.D. as Chief Financial Officer
April 01 2014 - 6:00AM
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology
company focused on the discovery and development of novel
diagnostics and therapeutics related to cell cycle dysregulation,
endoplasmic reticulum stress, neurodegeneration and apoptosis,
today announced the appointment of Mr. Robert Farrell, J.D. as
Chief Financial Officer. Mr. Farrell brings over 20 years of
healthcare, public company and CFO experience to Amarantus. Mr.
Marc Faerber will continue with Amarantus in his new role as
Corporate Controller and Vice President of Financial Operations.
"Amarantus is very well positioned to generate significant
shareholder value through the further development and
commercialization of its key assets in the months and years ahead,"
said Mr. Farrell, Amarantus' newly appointed Chief Financial
Officer. "I am pleased to be joining now at this critical juncture
as the Company prepares to uplist its common shares to a national
stock exchange in 2014 as we commercialize LymPro, initiate a Phase
2B clinical trial for Eltoprazine in Parkinson's disease and
prepare the MANF Program for an orphan drug designation submission.
We expect 2014 to be a transformative year for Amarantus as we lay
the groundwork for long-term shareholder value creation."
Mr. Farrell served as Chief Financial Officer of Titan
Pharmaceuticals from 1996 to 2008, and as President and CEO from
2008 to 2010. During his tenure at Titan Mr. Farrell was
responsible for all SEC filings, fund raising, financial and tax
planning strategies, mergers & acquisitions, corporate
partnerships, licensing transactions and financial operations,
where he raised over $390M via public equity and non-dilutive
financings, including seven corporate partnerships. Mr. Farrell
most recently served as CFO at Sanovas, Inc. Mr. Farrell previously
served as CFO, Corporate Group Vice President and General Counsel
at Fresenius USA and Fresenius Medical Care where he completed 6
corporate partnership and M&A transactions totaling over $4B.
Mr. Farrell also previously served as the CFO for the Institute for
One World Health in San Francisco and currently serves on the Board
of Directors of Prime Genomics, Inc. Mr. Farrell holds a J.D. from
the University of California's Hastings School of Law.
"We are extremely pleased to add Robert Farrell to our team as
we begin to build momentum towards uplisting our common shares on a
national stock exchange in 2014," said Gerald E. Commissiong,
President & CEO of Amarantus. "I am excited to work closely
with Bob as we move our products ahead in order to maximize the
value of our equity and mitigate risks going forward. Bob will
bring invaluable experience to our team as we continue to build
Amarantus into a world class company dedicated to bringing
meaningful solutions to patients."
About Amarantus
Amarantus is a biotechnology company developing treatments and
diagnostics for diseases associated with neurodegeneration and
protein misfolding-related apoptosis. The Company has licensed
Eltoprazine ("Eltoprazine"), a phase 2b ready indication for
Parkinson's Levodopa induced dyskinesia and Adult ADHD. The Company
has an exclusive worldwide license to the Lymphocyte Proliferation
test ("LymPro Test(R)") for Alzheimer's disease and owns the
intellectual property rights to a therapeutic protein known as
Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is
developing MANF-based products as treatments for brain disorders.
Amarantus is a Founding Member of the Coalition for Concussion
Treatment (#C4CT), a movement initiated in collaboration with
Brewer Sports International seeking to raise awareness of new
treatments in development for concussions and nervous-system
disorders. The Company also owns intellectual property for the
diagnosis of Parkinson's disease ("NuroPro") and the discovery of
neurotrophic factors ("PhenoGuard"). For further information please
visit www.Amarantus.com, or connect with the Company on Facebook,
LinkedIn, Twitter and Google+.
Certain statements, other than purely historical information,
including estimates, projections, statements relating to our
business plans, objectives, and expected operating results, and the
assumptions upon which those statements are based, are
forward-looking statements. These forward-looking statements
generally are identified by the words "believes," "project,"
"expects," "anticipates," "estimates," "intends," "strategy,"
"plan," "may," "will," "would," "will be," "will continue," "will
likely result," and similar expressions. Forward-looking statements
are based on current expectations and assumptions that are subject
to risks and uncertainties which may cause actual results to differ
materially from the forward-looking statements. Our ability to
predict results or the actual effect of future plans or strategies
is inherently uncertain. Factors which could have a material
adverse effect on our operations and future prospects on a
consolidated basis include, but are not limited to: changes in
economic conditions, legislative/regulatory changes, availability
of capital, interest rates, competition, and generally accepted
accounting principles. These risks and uncertainties should also be
considered in evaluating forward-looking statements and undue
reliance should not be placed on such statements.
CONTACT: Investor/Media Contacts
Aimee Boutcher, Director of Investor Relations
Amarantus Bioscience Holdings, Inc.
408-737-2734 x 101
ir@amarantus.com
Amarantus Bioscience (CE) (USOTC:AMBS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Amarantus Bioscience (CE) (USOTC:AMBS)
Historical Stock Chart
From Sep 2023 to Sep 2024